Hemgenix Disease Interactions
There are 2 disease interactions with Hemgenix (etranacogene dezaparvovec).
Etranacogene dezaparvovec (applies to Hemgenix) hepatic cancer
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Hepatitis, Liver Disease, Alcoholism
Therapy with etranacogene dezaparvovec may increase the risk of hepatocellular carcinoma development. Patients with preexisting risk factors for hepatocellular cancer such as cirrhosis, advanced hepatic fibrosis, hepatitis B or C, non-alcoholic fatty liver disease, alcoholism, non-alcoholic steatohepatitis, and advanced age should be monitored annually with a liver ultrasound and alpha-fetoprotein testing during 5 years following administration. The safety and efficacy of this drug in patients with severe hepatic impairment has not been studied.
References
- (2022) "Product Information. Hemgenix (46-50 kg) (etranacogene dezaparvovec)." CSL Behring LLC
Etranacogene dezaparvovec (applies to Hemgenix) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
The safety and efficacy of etranacogene dezaparvovec in patients with severe renal impairment and end-stage renal disease have not been studied. Caution is advised.
References
- (2022) "Product Information. Hemgenix (46-50 kg) (etranacogene dezaparvovec)." CSL Behring LLC
Hemgenix drug interactions
There are 31 drug interactions with Hemgenix (etranacogene dezaparvovec).
More about Hemgenix (etranacogene dezaparvovec)
- Hemgenix consumer information
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous uncategorized agents
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.